• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Kramer Hilary

    6/3/25 4:15:22 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTBP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Kramer Hilary

    (Last) (First) (Middle)
    C/O GT BIOPHARMA, INC.
    505 MONTGOMERY STREET, 10TH FLOOR

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/07/2025
    3. Issuer Name and Ticker or Trading Symbol
    GT Biopharma, Inc. [ GTBP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Hilary Kramer 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GTBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTBP

    DatePrice TargetRatingAnalyst
    12/2/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

    Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas

    7/6/26 11:19:00 AM ET
    $CTMX
    $GTBP
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

    Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural

    6/30/26 9:00:00 AM ET
    $CMPX
    $FATE
    $GTBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

    Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p

    6/12/26 8:10:00 AM ET
    $CMPX
    $CRBU
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mun-Gavin David C.

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:44 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and Director Breen Michael Martin

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:43 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Casamento Charles J

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:40 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on GT Biopharma with a new price target

    ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

    12/2/24 10:00:20 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on GT Biopharma with a new price target

    HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

    5/24/21 6:11:36 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on GT Biopharma with a new price target

    B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00

    4/13/21 6:45:30 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    SEC Filings

    View All

    SEC Form DEF 14A filed by GT Biopharma Inc.

    DEF 14A - GT Biopharma, Inc. (0000109657) (Filer)

    7/2/26 4:30:32 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by GT Biopharma Inc.

    PRE 14A - GT Biopharma, Inc. (0000109657) (Filer)

    6/18/26 4:45:29 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    6/12/26 4:30:27 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

    6/13/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

    5/14/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Financials

    Live finance-specific insights

    View All

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m

    5/14/26 10:55:00 AM ET
    $GTBP
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter to Research Solutions, Inc. Shareholders

    Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t

    8/4/23 9:30:41 AM ET
    $GTBP
    $RSSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    5/23/24 8:31:08 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    2/14/24 2:46:25 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GT Biopharma Inc.

    SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

    9/19/23 11:56:06 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care